Guru P. Sonpavde: Are rational combinations of antibody-drug-conjugates a viable paradigm for future drug development?

Guru P. Sonpavde, Phase I and GU Oncology Director at Advent Health Cancer Institute, recently shared on X/Twitter:

ESMO23 preview:

Are rational combinations of antibody-drug-conjugates a viable paradigm for future drug development? Look for data from the DAD trial, ESMO that I was honored to propose and launch with support from Gilead Oncology and Dana-Farber Lank Center for Genitourinary Oncology – this is as an oral presentation by my colleague Bradley McGregor, Dana-Farber- Phase I trial of sacituzumab govitecan + enfortumab vedotin for metastatic urothelial carcinoma -rationale includes points I learned from the legendary Dr. Larry Einhorn, Indiana University, during my fellowship:
1) Both drugs have proven single agent activity and benefits,
2) Non-overlapping surface membrane targets (Trop2, Nectin4),
3) Different payloads (Topo-1 inhibitor SN38, tubulin inhibitor MMAE),
4) Largely non-overlapping toxicities (myelosuppression, diarrhea vs rash, neuropathy, hyperglycemia).

Source: Guru P. Sonpavde/Twitter